

Special Issue

Advances in Vaccine Biomanufacturing Processes

Message from the Guest Editor

The aim of this special issue is to present significant advances made in bioprocessing for the robust, rapid, flexible and cost-efficient manufacturing of vaccines. Contributions are welcomed on a range of themes, including process intensification of upstream and downstream operations allowing improved productivity and increased product yield and purity, the development and application of new process analytical technologies to support process development and analyses of the product quality attributes, the design of novel monitoring tools and control strategies to ensure process consistency and performance, the application of new high-throughput technologies and Quality by Design approaches for vaccine manufacturing, as well as the devise of new cell line platforms, innovative bioreactor designs and downstream processing techniques. Since rational process development and optimization are highly dependent on a good understanding of the complex production steps and interactions between cells and virus, contributions related to the modelling of cell culture kinetics, as well as the application of systems biology and metabolic engineering approaches are also welcomed.

Guest Editor

Prof. Dr. Olivier Henry

Department of Chemical Engineering, Polytechnique Montréal,
Montréal, QC, Canada

Deadline for manuscript submissions

closed (20 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/94494

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).